Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 14 Show results per page	View Search Criteria \| Help With Results

	Title				Phase				Protocol IDs

	Mycobacterial Cell Wall-DNA Complex in Treatment of BCG-Refractory Patients With Non-Muscle Invasive Bladder Cancer				Phase III, Phase II				HIS-0611-0602 NCT00406068
	Gemcitabine After Surgery in Treating Patients With Newly Diagnosed or Recurrent Bladder Cancer				Phase III				SWOG-S0337 S0337, NCT00445601
	Trial of Single-Dose Intravesical EOquin® as a Surgical Adjuvant Instilled in the Early Postoperative Period in Patients Undergoing TUR-BT				Phase III				SPI-611 NCT00461591
	Phase 3 Trial of Single-Dose Intravesical EOquin® as a Surgical Adjuvant for Noninvasive Bladder Cancer				Phase III				SPI-612 NCT00598806
	Sequential Whole Bladder Photodynamic Therapy (WBPDT) in the Management of Superficial Bladder Cancer				Phase II, Phase I				WBPDT-577-04 NCT00322699
	Phase I & II Trial of Intravesicular Abraxane for Treatment-Refractory Bladder Cancer				Phase II, Phase I				AAAC1114 NCT00583349
	Gemcitabine in Treating Patients With Recurrent Bladder Cancer That Has Not Responded to Previous Bacillus Calmette-Guerin				Phase II				SWOG-S0353 S0353, NCT00234039
	Phase 2b, Trial of Intravesical DTA-H19/PEI in Patients With Intermediate-Risk Superficial Bladder Cancer				Phase II				BC-07-01.CTIL NCT00595088
	Neoadjuvant Erlotinib (Tarceva) in Transitional Cell Carcinoma				Phase II				2007-0704 NCT00749892
	Merits of Performing a Modified Template Retroperitoneal Lymph Node Dissection				Phase II				MCC-15441 IRB 10718, NCT00751140


					1 2 Next >

| | | | | | | |

A Service of the National Cancer Institute